Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal
Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
Meiji Seika Pharma wins EU orphan drug status for morcamilast in palmoplantar pustulosis
EU orphan status for morcamilast in PPP reshapes Meiji Seika Pharma’s European strategy. See what it means for PDE4 competition and rare dermatology.
Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?
Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.
Takeda and Protagonist near FDA decision on novel PV therapy rusfertide
FDA grants Priority Review to rusfertide for polycythemia vera. Discover what this means for treatment standards and market dynamics.
Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.
Biocytogen and IDEAYA Biosciences push IDE034 into the clinic as dual-antigen ADC strategies mature
IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.
Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma
KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.
Why Merck and Eisai’s belzutifan–lenvatinib combo could reset treatment sequencing in advanced renal cell carcinoma
Belzutifan plus lenvatinib outperforms cabozantinib in Phase 3 renal cell carcinoma data. Find out what this changes for post-immunotherapy care.
Sciwind Biosciences and Pfizer China bet on ecnoglutide as China’s GLP-1 market enters its most competitive phase
Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.